Advanced searches left 3/3

Multicenter Clinical Trial - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 25 July 2022

* If you want to update the article please login/register

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Patients with an acute ischemic stroke with occlusion of an intracranial vessel of the anterior circulation and an occlusion or severe stenosis of the origins of the ipsilateral internal carotid artery are classified as patients with tandem lesions. The new clinical practice guidelines in relation to this antiplatelet regimen warn about the danger of mixing intravenous fibrinolysis with antiplatelet drugs in the acute phase, owing to the risk of symptomatic intracranial hemorrhage. However, non-stabilization of the carotid atheroma plaque is associated with increased rates of cervical reocclusion, poorer functional prognosis, and increased mortality. The investigators plan to conduct a prospective multicenter randomized clinical trial to determine the best protocol for mono-antiaggregant therapy in the acute phase of TL. To establish the most appropriate regimen for mono-antiaggregant therapy, the investigators suggest that we conduct a prospective multicenter randomized clinical trial. Patients with ischemic stroke secondary to TL in the anterior circulation candidates for mechanical thrombectomy in whom cervical endoprosthesis will be present in the acute phase will be included in two groups, randomized to 500 mg of intravenous Aspirin in Tirofiban iv. After mechanical thrombectomy, Carotid thrombectomy rates and sICH rates will be assessed within the first 24 hours. Establishing an antiplatelet management protocol in the acute phase in these patients would be an innovative step that could not be developed by any other group worldwide, and it would put us at the forefront of research in the field.

Source link: https://clinicaltrials.gov/ct2/show/NCT05225961


A Prospective, Open-label, Genotype-match Controlled, Multicenter Clinical Trial to Investigate the Efficacy and Safety of Intra-amniotic ER004 as a Prenatal Treatment for Male Subjects With XLHED

It is a rare developmental disorder affecting body organs that are derived from the embryonal ectoderm. The replacement of the missing EDA1 protein in patients with XLHED is the proposed method of action by ER004's XLHED patients. Male XLHED fetuses/subjects with EDA mutation diagnosis confirmed by genetic analysis of a mutation in one of the maternal EDA alleles and ultrasonographic diagnosis of a significantly reduced number of fetal tooth germs, as well as a documented clinical diagnosis of a hemizygous EDA mutation (EDA mutation). The mothers' wellbeing will be determined up to six months of age and safety will be assessed up to 1 month after delivery of the child. When available, Treated subjects sweating ability will be comparable to untreated relative from his family, or a closely matched controlled subject from a previous natural history.

Source link: https://clinicaltrials.gov/ct2/show/NCT04980638


Immunogenicity and Reactogenicity Following a 3rd Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered as a Booster in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination: A Randomized, Single-blinded Multicenter Clinical Trial

In real life, the effectiveness of COVID 19 vaccines for lowering the risk of severe COVID-19 infections has now been demonstrated. Pfizer-BionTech mRNA vaccine was administered in a trial by a booster dose of either recombinant protein-based subunit vaccine or by a booster dose of Pfizer-BioNTech mRNA vaccine in people who had been vaccinationed with two doses of Pfizer-BionTech mRNA vaccine. 20-64 years old Group 1. B: 65 years and older ARM 2 receiving SP/GSK subunit B. 1. 351 vaccine; ARM 1: 65 years old, Pfizer-British vaccine Group 2. 01: 70 years and older; 65 years old Group 2. B. 65 years and older with three parallel arms: Three-B: 65 years old Group 2. B: 65 years and older than the former military service; a global network analysis, blood draw, and administration of the booster dose 1. B: 36 years old Group village, : ARM 1. B: 65 years old Group 2. A: hearteted; B.

Source link: https://clinicaltrials.gov/ct2/show/NCT05124171

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions